Inovio Product Pipeline: Infectious Disease DNA Vaccines
DNA vaccine technology has created the potential for a new generation of infectious disease vaccines with not only preventive but therapeutic capabilities. Inovio has a proprietary DNA vaccine candidate for HIV in Phase I clinical studies, an avian influenza candidate awaiting IND approval, and multiple R&D programs for different infectious diseases. Many of these programs are being conducted and/or funded in collaboration with respected research organizations.
License partners and other collaborators are also using Inovio's electroporation DNA delivery technology to facilitate their vaccine research.
Multiple clinical studies are progressing and are described in the following sections.